Could a Stop-Smoking drug curb heavy drinking in HIV patients?

NCT ID NCT06006143

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether giving the smoking-cessation drug varenicline to people with HIV who also have alcohol use disorder is practical and safe. Thirty participants will receive the medication along with support from a pharmacist and psychiatrist. The goal is to see if this approach can reduce alcohol use, but the study is small and early, so results will be preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

varenicline

What this could lead to

If this works, it could point toward a practical way to help people with HIV reduce heavy drinking using an existing medication.

What could go wrong

This is a very small pilot study with only 30 participants, no placebo group, and it's not designed to prove the drug works. The medication is being used off-label, so unexpected side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS alcohol abuse HIV infectious disease nicotine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta VA Medical Center

    Decatur, Georgia, 30033, United States